Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology

Jason Gotlib, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Eric Padron, Philip Pancari, Nikolaos Papadantonakis, Animesh Pardanani, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim & 9 others Lindsay Rein, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Martha Wadleigh, Katherine Walsh, Mary Anne Bergman, Hema Sundar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.

Original languageEnglish (US)
Pages (from-to)1500-1537
Number of pages38
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Systemic Mastocytosis
Practice Guidelines
Mastocytosis
Mast Cells
Skin
Guidelines
Mutation
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., ... Sundar, H. (2018). Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 16(12), 1500-1537. https://doi.org/10.6004/jnccn.2018.0088

Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology. / Gotlib, Jason; Gerds, Aaron T.; Bose, Prithviraj; Castells, Mariana C.; Deininger, Michael W.; Gojo, Ivana; Gundabolu, Krishna; Hobbs, Gabriela; Jamieson, Catriona; McMahon, Brandon; Mohan, Sanjay R.; Oehler, Vivian; Oh, Stephen; Padron, Eric; Pancari, Philip; Papadantonakis, Nikolaos; Pardanani, Animesh; Podoltsev, Nikolai; Rampal, Raajit; Ranheim, Erik; Rein, Lindsay; Snyder, David S.; Stein, Brady L.; Talpaz, Moshe; Thota, Swapna; Wadleigh, Martha; Walsh, Katherine; Bergman, Mary Anne; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 12, 01.12.2018, p. 1500-1537.

Research output: Contribution to journalArticle

Gotlib, J, Gerds, AT, Bose, P, Castells, MC, Deininger, MW, Gojo, I, Gundabolu, K, Hobbs, G, Jamieson, C, McMahon, B, Mohan, SR, Oehler, V, Oh, S, Padron, E, Pancari, P, Papadantonakis, N, Pardanani, A, Podoltsev, N, Rampal, R, Ranheim, E, Rein, L, Snyder, DS, Stein, BL, Talpaz, M, Thota, S, Wadleigh, M, Walsh, K, Bergman, MA & Sundar, H 2018, 'Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 12, pp. 1500-1537. https://doi.org/10.6004/jnccn.2018.0088
Gotlib, Jason ; Gerds, Aaron T. ; Bose, Prithviraj ; Castells, Mariana C. ; Deininger, Michael W. ; Gojo, Ivana ; Gundabolu, Krishna ; Hobbs, Gabriela ; Jamieson, Catriona ; McMahon, Brandon ; Mohan, Sanjay R. ; Oehler, Vivian ; Oh, Stephen ; Padron, Eric ; Pancari, Philip ; Papadantonakis, Nikolaos ; Pardanani, Animesh ; Podoltsev, Nikolai ; Rampal, Raajit ; Ranheim, Erik ; Rein, Lindsay ; Snyder, David S. ; Stein, Brady L. ; Talpaz, Moshe ; Thota, Swapna ; Wadleigh, Martha ; Walsh, Katherine ; Bergman, Mary Anne ; Sundar, Hema. / Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2018 ; Vol. 16, No. 12. pp. 1500-1537.
@article{c30eb38697bd42d6a0db22edffdf9739,
title = "Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology",
abstract = "Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.",
author = "Jason Gotlib and Gerds, {Aaron T.} and Prithviraj Bose and Castells, {Mariana C.} and Deininger, {Michael W.} and Ivana Gojo and Krishna Gundabolu and Gabriela Hobbs and Catriona Jamieson and Brandon McMahon and Mohan, {Sanjay R.} and Vivian Oehler and Stephen Oh and Eric Padron and Philip Pancari and Nikolaos Papadantonakis and Animesh Pardanani and Nikolai Podoltsev and Raajit Rampal and Erik Ranheim and Lindsay Rein and Snyder, {David S.} and Stein, {Brady L.} and Moshe Talpaz and Swapna Thota and Martha Wadleigh and Katherine Walsh and Bergman, {Mary Anne} and Hema Sundar",
year = "2018",
month = "12",
day = "1",
doi = "10.6004/jnccn.2018.0088",
language = "English (US)",
volume = "16",
pages = "1500--1537",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",

}

TY - JOUR

T1 - Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology

AU - Gotlib, Jason

AU - Gerds, Aaron T.

AU - Bose, Prithviraj

AU - Castells, Mariana C.

AU - Deininger, Michael W.

AU - Gojo, Ivana

AU - Gundabolu, Krishna

AU - Hobbs, Gabriela

AU - Jamieson, Catriona

AU - McMahon, Brandon

AU - Mohan, Sanjay R.

AU - Oehler, Vivian

AU - Oh, Stephen

AU - Padron, Eric

AU - Pancari, Philip

AU - Papadantonakis, Nikolaos

AU - Pardanani, Animesh

AU - Podoltsev, Nikolai

AU - Rampal, Raajit

AU - Ranheim, Erik

AU - Rein, Lindsay

AU - Snyder, David S.

AU - Stein, Brady L.

AU - Talpaz, Moshe

AU - Thota, Swapna

AU - Wadleigh, Martha

AU - Walsh, Katherine

AU - Bergman, Mary Anne

AU - Sundar, Hema

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.

AB - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.

UR - http://www.scopus.com/inward/record.url?scp=85058725553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058725553&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0088

DO - 10.6004/jnccn.2018.0088

M3 - Article

VL - 16

SP - 1500

EP - 1537

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 12

ER -